McAfee+ Premium’s excellent ‘unlimited device’ antivirus could make it a smart choice for anyone with lots of hardware to ...

Vironexis Biotherapeutics emerged from stealth with plans to start what it claims will be the first-ever clinical trial testing a cancer immunotherapy delivered with the help of an adeno-associated ...

Big news! Amazon Prime Day is coming back this October and ahead of the sale you can get free audiobooks with an Audible ...

30 and will give each customer one month of access. At the conclusion of the trial period, NFL+ Premium will renew automatically unless canceled. Want to bet on Falcons-Eagles? Follow these steps ...

It started more than a year ago, took nearly 50 days in a courtroom and may not be decided until next year, but the trial of two leaders of the 2022 "Freedom Convoy" protest in Ottawa finally ...

After 45 days of evidence and legal arguments the criminal trial of "Freedom Convoy" organizers Tamara Lich and Chris Barber is finally at an end. A verdict could be as much as six months away.

Video / Corey Fleming Done. All over, the last little drops of evidence squeezed out at 12.26pm on Friday in the murder trial of Dr Philip Polkinghorne, on day 31 of an epic seven-week ordeal at ...

The first time you install Malwarebytes Anti-Malware, you’re given a 14-day trial of the premium edition, which includes preventative tools like real-time scanning and specific protection from ...

An unknown attacker is exploiting weak passwords to break into Oracle WebLogic servers and deploy an emerging Linux malware called Hadooken, according to researchers from cloud security outfit Aqua.

The recently observed Hadooken malware targeting Oracle WebLogic applications is linked to multiple ransomware families. A new Linux malware has been observed targeting Oracle WebLogic servers to ...

Please verify your email address. Fitbit Premium subscribers can access Peloton classes for workouts like running, cycling, yoga, and more. Pixel Watch 3 owners receive a free six-month Fitbit ...

NEW YORK – NKGen Biotech announced Thursday that it has dosed the first patient in the Phase II portion of a Phase I/IIa clinical trial testing the activity of its autologous natural killer cell ...